· Vision and Mission
Qizheng Tibetan Medicine Included in the Shenzhen Stock Exchange’s Pilot Program for Direct Information Disclosure.
Release time:
2012-07-11 14:51
Lhasa, July 11 (People's Daily Online, reporter Yang Qingjun) — Recently, the Shenzhen Stock Exchange completed its assessment of information disclosure practices for listed companies on the Main Board, the SME Board, and the ChiNext Board for the year 2011. Qizheng Tibetan Medicine received an “Excellent” rating and has been included in the pilot group of companies eligible for the “Information Disclosure Express Lane.” It is currently the first listed company in the Tibet Autonomous Region to be selected for this initiative.
It is reported that this is the first assessment conducted by the Shenzhen Stock Exchange since it revised the “Regulations on the Assessment of Information Disclosure by Listed Companies” in 2011. The new regulations provide a comprehensive assessment covering aspects such as information disclosure, standardized operations, regulatory measures, and penalties for violations. The assessment results are categorized into four levels: A, B, C, and D. In total, 646 companies listed on the SME Board of the Shenzhen Stock Exchange participated in the assessment; among them, 131 companies received an A rating (excellent), accounting for 20.28% of all listed companies that took part in the assessment.
Relevant personnel from Qizheng Tibetan Medicine stated that since the company’s listing on the Shenzhen Stock Exchange in August 2009, it has strictly complied with all regulatory requirements issued by the China Securities Regulatory Commission (CSRC), the Shenzhen Stock Exchange, and other regulatory authorities. The company has effectively implemented its internal regulations, including the “Information Disclosure Management System” and the “Internal Reporting System for Material Information.” As of 2011, Qizheng Tibetan Medicine had disclosed a total of 94 announcements involving 186 documents, ensuring that its information disclosure efforts were truthful, accurate, and complete, with no false statements, misleading statements, or material omissions. This has effectively enabled information disclosure to play a positive guiding role in promoting the company’s standardized operations.
It is understood that including companies whose information disclosure efforts have been rated highly on the pilot list for the “Information Disclosure Express Lane” represents a major institutional innovation introduced by the Shenzhen Stock Exchange in 2011. Under this system, listed companies whose information disclosure performance was rated excellent by the SZSE in the previous year are exempted from prior review by the SZSE when disclosing certain announcements this year.
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO